Drugs / Lu-DOTA-TATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01876771 | Apr 2014 → Dec 2042 expected | neuroendocrine carcinoma | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-DOTA-TATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01876771 ↗ |
| Known as | Lutetium-177 [DOTA0, Tyr3] Octreotate | “An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours” NCT01876771 ↗ |